

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mark A. OLSON, et al.

Serial No.: 10/083,336

Filed: 27 February 2002

For: RICIN VACCINE AND METHODS OF
MAKING AND USING THEREOF

Group Art Unit: 1652

Examiner: Rao, Manjunath N.

Atty Dkt No.: P67452US0 (RIID 01-58)

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Restriction Requirement mailed 22 May 2003, wherein the Examiner required a restriction of claims 1-24 in the above-referenced patent application.

AMENDMENT

IN THE CLAIMS:

Please amend the claims as follows:

- B¹
1. (Original) An isolated polypeptide or variant thereof comprising a polypeptide sequence having substantial identity to a wild type ricin A chain first globular domain sequence and lacks detectable N-glycosidase-rRNA activity or exhibits reduced N-glycosidase-rRNA activity as compared to a control.
 2. (Original) The polypeptide of claim 1, wherein the polypeptide retains the functional integrity of the neutralizing immunological epitope of wild type ricin A chain.
 3. (Original) The polypeptide of claim 1, wherein the polypeptide has an aqueous solubility that is greater than the solubility of wild type ricin A chain.

9/B
MQJ
7/2/03
RECEIVED

JUN 24 2003
TECH CENTER 1600/2900